Kenvue (KVUE) Scheduled to Post Earnings on Thursday

Kenvue (NYSE:KVUE) is scheduled to post its quarterly earnings results before the market opens on Thursday, November 7th. Analysts expect Kenvue to post earnings of $0.27 per share for the quarter. Kenvue has set its FY24 guidance at $1.10-1.20 EPS and its FY 2024 guidance at 1.100-1.200 EPS.Investors interested in registering for the company’s conference call can do so using this link.

Kenvue (NYSE:KVUE) last issued its earnings results on Tuesday, August 6th. The company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.04. Kenvue had a net margin of 7.23% and a return on equity of 21.80%. The firm had revenue of $4 billion during the quarter, compared to the consensus estimate of $3.93 billion. During the same quarter in the previous year, the firm posted $0.32 earnings per share. The company’s revenue was down .3% compared to the same quarter last year. On average, analysts expect Kenvue to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Kenvue Stock Up 0.5 %

Kenvue stock opened at $22.90 on Thursday. The stock’s fifty day moving average is $22.48 and its two-hundred day moving average is $20.36. The stock has a market cap of $43.85 billion, a PE ratio of 29.36, a P/E/G ratio of 3.00 and a beta of 1.40. Kenvue has a 1-year low of $17.67 and a 1-year high of $23.55. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.99 and a quick ratio of 0.68.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th will be paid a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a yield of 3.58%. The ex-dividend date is Wednesday, November 13th. Kenvue’s payout ratio is 105.13%.

Analysts Set New Price Targets

KVUE has been the topic of several recent analyst reports. Jefferies Financial Group started coverage on shares of Kenvue in a research note on Tuesday, September 24th. They issued a “buy” rating and a $27.00 price target on the stock. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Bank of America raised their price objective on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. Royal Bank of Canada downgraded Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 target price for the company. in a report on Tuesday, September 24th. Finally, UBS Group raised their price target on Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $22.64.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.